Pharmacokinetics and pharmacodynamics of levodopa

被引:110
|
作者
Nutt, John G. [1 ]
机构
[1] Oregon Hlth & Sci Univ, Dept Neurol, Parkinson Dis Res Educ & Clin Ctr, Portland Va, OR 97239 USA
关键词
levodopa; short-duration response; motor fluctuations; dyskinesia;
D O I
10.1002/mds.22037
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The pharmacokinetics and pharmacodynamics of levodopa are dominated by two features: the Short plasma half-fife of the drug and the portion of the antiparkinsonian response that parallels the plasma levodopa levels. the so-called short-duration response. These features are the basis of Motor fluctuations that complicate long-term therapy with levodopa. Motor fluctuations will predictably improve with measures that prolong the elevations of plasma levodopa or prolong the efficacy of dopamine synthesized from exogenous levodopa. Because dyskinesia is closely linked to the short-duration response and conceivably part of the short-duration response, it is less clear that dyskinesia will be improved by therapeutic strategies that reduce motor fluctuations. (c) 2008 Movement Disorder Society.
引用
收藏
页码:S580 / S584
页数:5
相关论文
共 50 条
  • [1] PHARMACOKINETICS AND PHARMACODYNAMICS OF LEVODOPA
    MONTGOMERY, EB
    NEUROLOGY, 1992, 42 (01) : 17 - 22
  • [2] LEVODOPA - PHARMACOLOGY, PHARMACOKINETICS, AND PHARMACODYNAMICS
    JUNCOS, JL
    NEUROLOGIC CLINICS, 1992, 10 (02) : 487 - 509
  • [3] The effect of exercise on pharmacokinetics and pharmacodynamics of levodopa
    Reuter, I
    Harder, S
    Engelhardt, M
    Baas, H
    MOVEMENT DISORDERS, 2000, 15 (05) : 862 - 868
  • [4] Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics
    Kompoliti, K
    Adler, CH
    Raman, R
    Pincus, JH
    Leibowitz, MT
    Ferry, JJ
    Blasucci, L
    Caviness, JN
    Leurgans, S
    Chase, WM
    Yones, LC
    Tan, E
    Carvey, P
    Goetz, CG
    NEUROLOGY, 2002, 58 (09) : 1418 - 1422
  • [5] Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics
    Zappia, M
    Quattrone, A
    NEUROLOGY, 2002, 59 (12) : 2010 - 2010
  • [6] Effects of caffeine on levodopa pharmacokinetics and pharmacodynamics in Parkinson disease
    Deleu, D.
    Jacob, P.
    Chand, P.
    Sarre, S.
    Colwell, A.
    NEUROLOGY, 2006, 67 (05) : 897 - 899
  • [7] Levodopa Therapy for Parkinson's Disease: Pharmacokinetics and Pharmacodynamics
    LeWitt, Peter A.
    MOVEMENT DISORDERS, 2015, 30 (01) : 64 - 72
  • [8] The Pharmacokinetics and Pharmacodynamics of Levodopa in the Treatment of Parkinson's Disease
    Khor, Soo-Peang
    Hsu, Ann
    CURRENT CLINICAL PHARMACOLOGY, 2007, 2 (03): : 234 - 243
  • [9] LEVODOPA PHARMACOKINETICS AND PHARMACODYNAMICS IN FLUCTUATING PARKINSONIAN-PATIENTS
    NUTT, JG
    WOODWARD, WR
    NEUROLOGY, 1986, 36 (06) : 739 - 744
  • [10] Population pharmacokinetics and pharmacodynamics of oral levodopa in parkinsonian patients
    Triggs, EJ
    Charles, BG
    Contin, M
    Martinelli, P
    Cortelli, P
    Riva, R
    Albani, F
    Baruzzi, A
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 51 (01) : 59 - 67